Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Fresenius Kabi Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (286)
Cancellation by sponsor (126)
Prescription medicine registration (12)
Australian Public Assessment Report (AusPAR) (6)
Prescription medicine decision summary (2)

Date

2024 (46)
2023 (45)
2022 (29)
2021 (13)
2020 (31)
2019 (59)
2018 (17)
2017 (14)
2016 (18)
2015 (23)
2014 (8)
2013 (26)
2012 (18)
2011 (5)
2010 (5)
2009 (1)
2008 (13)
2007 (13)
2006 (26)
2002 (2)
2001 (3)
1994 (7)
1992 (3)
1991 (7)

Results for "[search-keyword]"

Search

Sponsor content

432 result(s) found, displaying 31 to 40

FRESOFOL 1% propofol 1g/100mL injection vial Cancelled under Section 30(1)(c) of the Act

24 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
FRESOFOL 1% propofol 500mg/50mL injection vial Cancelled under Section 30(1)(c) of the Act

24 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
FRESOFOL 1% propofol 200mg/20mL injection ampoule Cancelled under Section 30(1)(c) of the Act

24 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
Fresenius Kabi Australia Pty Ltd - Infusion pump management unit, mobile (444654)

27 March 2024

ARTG

Australian Register of Therapeutic Goods (ARTG) information for Fresenius Kabi Australia Pty Ltd - Infusion pump management unit, mobile.
KABIVEN G 11% 2400mL injection bag Cancelled under Section 30(1)(c) of the Act

13 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
KABIVEN G 11% 1920mL injection bag Cancelled under Section 30(1)(c) of the Act

13 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
KABIVEN G 19% 1026mL injection bag Cancelled under Section 30(1)(c) of the Act

13 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
GLAMIN amino acids/dipeptides 1000mL intravenous infusion injection bottle Cancelled under Section 30(1)(c) of the Act

13 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
INTRALIPID 30% 333mL injection bag Cancelled under Section 30(1)(c) of the Act

13 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
INTRALIPID 30% 250mL injection bag Cancelled under Section 30(1)(c) of the Act

13 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd

Pages

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.